» Articles » PMID: 37969654

Incorporating Exercise Training Into Cardio-Oncology Care: Current Evidence and Opportunities: State-of-the-Art Review

Overview
Date 2023 Nov 16
PMID 37969654
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer treatment-induced cardiotoxicities are an ongoing concern throughout the cancer care continuum from treatment initiation to survivorship. Several "standard-of-care" primary, secondary, and tertiary prevention strategies are available to prevent the development or further progression of cancer treatment-induced cardiotoxicities and their risk factors. Despite exercise's established benefits on the cardiovascular system, it has not been widely adopted as a nonpharmacologic cardioprotective strategy within cardio-oncology care. In this state-of-the-art review, the authors discuss cancer treatment-induced cardiotoxicities, review the existing evidence supporting the role of exercise in preventing and managing these sequelae in at-risk and affected individuals living after cancer diagnoses, and propose considerations for implementing exercise-based services in cardio-oncology practice.

Citing Articles

Cancer Diagnosis, Physical Activity, and Heart Disease Risk.

Stamatakis E, Koemel N, Biswas R, Ahmadi M JACC CardioOncol. 2025; 6(6):890-892.

PMID: 39801641 PMC: 11712014. DOI: 10.1016/j.jaccao.2024.11.002.


The role of physical exercise in cancer therapy-related CV toxicity.

Mattioli A, Bucciarelli V, Gallina S Future Cardiol. 2025; 21(3):131-134.

PMID: 39779253 PMC: 11875471. DOI: 10.1080/14796678.2025.2451530.


The Digital Revolution in Medicine: Applications in Cardio-Oncology.

Echefu G, Batalik L, Lukan A, Shah R, Nain P, Guha A Curr Treat Options Cardiovasc Med. 2024; 27(1).

PMID: 39610711 PMC: 11600984. DOI: 10.1007/s11936-024-01059-x.


Anthracycline Cardiotoxicity in Adult Cancer Patients: State-of-the-Art Review.

Camilli M, Cipolla C, Dent S, Minotti G, Cardinale D JACC CardioOncol. 2024; 6(5):655-677.

PMID: 39479333 PMC: 11520218. DOI: 10.1016/j.jaccao.2024.07.016.


Cardioprotection strategies for anthracycline cardiotoxicity.

Moreno-Arciniegas A, Cadiz L, Galan-Arriola C, Clemente-Moragon A, Ibanez B Basic Res Cardiol. 2024; 120(1):71-90.

PMID: 39249555 PMC: 11790697. DOI: 10.1007/s00395-024-01078-6.


References
1.
Michael C, Lehrer E, Schmitz K, Zaorsky N . Prehabilitation exercise therapy for cancer: A systematic review and meta-analysis. Cancer Med. 2021; 10(13):4195-4205. PMC: 8267161. DOI: 10.1002/cam4.4021. View

2.
Kerrigan D, Reddy M, Walker E, Cook B, McCord J, Loutfi R . Cardiac Rehabilitation Improves Fitness in Patients With Subclinical Markers of Cardiotoxicity While Receiving Chemotherapy: A RANDOMIZED CONTROLLED STUDY. J Cardiopulm Rehabil Prev. 2022; 43(2):129-134. DOI: 10.1097/HCR.0000000000000719. View

3.
Richardson W, Wilson M, Nishikawa J, Hayward R . The well-built clinical question: a key to evidence-based decisions. ACP J Club. 1995; 123(3):A12-3. View

4.
Haykowsky M, Mackey J, Thompson R, Jones L, Paterson D . Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training. Clin Cancer Res. 2009; 15(15):4963-7. DOI: 10.1158/1078-0432.CCR-09-0628. View

5.
Hojan K, Procyk D, Horynska-Kestowicz D, Leporowska E, Litwiniuk M . The Preventive role of Regular Physical Training in Ventricular Remodeling, Serum Cardiac Markers, and Exercise Performance Changes in Breast Cancer in Women Undergoing Trastuzumab Therapy-An REH-HER Study. J Clin Med. 2020; 9(5). PMC: 7291322. DOI: 10.3390/jcm9051379. View